Compare TBPH & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | RCAT |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Wholesale Distributors |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 957.4M |
| IPO Year | N/A | 2017 |
| Metric | TBPH | RCAT |
|---|---|---|
| Price | $20.04 | $13.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $27.80 | $14.50 |
| AVG Volume (30 Days) | 439.2K | ★ 12.8M |
| Earning Date | 02-25-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $80,327,000.00 | $7,443,942.00 |
| Revenue This Year | $70.78 | $396.50 |
| Revenue Next Year | N/A | $296.06 |
| P/E Ratio | $34.48 | ★ N/A |
| Revenue Growth | ★ 27.12 | N/A |
| 52 Week Low | $7.90 | $4.58 |
| 52 Week High | $20.79 | $16.70 |
| Indicator | TBPH | RCAT |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 72.77 |
| Support Level | $18.41 | $11.43 |
| Resistance Level | $20.79 | $14.65 |
| Average True Range (ATR) | 0.71 | 1.14 |
| MACD | 0.12 | 0.47 |
| Stochastic Oscillator | 76.62 | 86.70 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.